Gastrointestinal comorbidities associated with atrial fibrillation

SpringerPlus

Table 2 Treatment patterns of medications associated with GI conditions

Variable	All AF patients (N = 557,123)	AF patients without history of GI at baseline (N = 413,168)
Medications associated with GI, n (%)
Medications that may cause GI events^a	398,633 (71.6%)	298,490 (72.2%)
Medications used to treat GI events^b	225,833 (40.5%)	154,164 (37.3%)
Exposure to therapy^c, days, mean (SD)
Medications that may cause GI events^a	523.7 (452.7)	534.8 (456.5)
Medications used to treat GI events^b	392.6 (409.6)	383.1 (408.6)
Dispensings per patient, mean (SD)
Medications that may cause GI events^a	17.6 (21.2)	17.4 (20.8)
Medications used to treat GI events^b	7.4 (9.3)	7.0 (8.8)
Days of supply per dispensing per patient, mean (SD)
Medications that may cause GI events^a	34.7 (22.3)	35.5 (22.8)
Medications used to treat GI events^b	43.4 (28.6)	43.0 (29.2)
Anticoagulant and antiplatelet agents use, n (%)
Antiplatelet	66,790 (12.0%)	48,808 (11.8%)
Anticoagulant	208,985 (37.5%)	162,597 (39.4%)

AF atrial fibrillation, GI gastrointestinal.
^aIncluding anticoagulant, antiplatelet, corticosteroids, NSAIDs, SSRIs, calcium channel blockers, bisphosponates, antibiotic, pain medications (opioids), antineoplastic, anesthesia medication, medications used to treat poisonings, and iron-related medication.
^bIncluding antacids, antidiarrheals, antiemetics, digestive aids, gastrointestinal agents, laxatives, and ulcer drugs.
^cTime from the date of the first dispensing to the end of the days of supply for the last dispensing.